⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline
accessnewswire.com
ERAS
RVMD
Contact Levi & Korsinsky by August 10, 2026 to Join Class Action Against Erasca, Inc. (ERAS)
accessnewswire.com
ERAS
RVMD
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
ERAS
RVMD
ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
ERAS
RVMD
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
globenewswire.com
RVMD
MRNA
SRPT
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
globenewswire.com
RVMD
Facial Injectables Market to Surge From USD 15.64 Billion in 2026 to USD 29.94 Billion by 2036, Driven by Hyaluronic Acid Fillers and Botulinum Toxin Treatments
accessnewswire.com
ABBV
RVMD
Form 8-K
sec.gov
RVMD
RVMDW
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com
RVMD